The prevalence of weight loss during (chemo)radiotherapy treatment for lung cancer and associated patient- and treatment-related factors

Nicole Kiss, Elisabeth Isenring, Karla Gough, Meinir Krishnasamy

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)

Abstract

BACKGROUND & AIMS: Thoracic radiotherapy is associated with toxicities that can adversely impact nutritional intake. This study aimed to investigate the prevalence and predictors of ≥5% weight loss and commencement of enteral nutrition in lung cancer patients receiving radiotherapy.

METHODS: A retrospective study of 96 patients treated with high dose palliative or radical radiotherapy for a primary diagnosis of small cell or non-small cell lung cancer. Weight loss was calculated between the start and up to 90 days from radiotherapy commencement. Associations between ≥5% weight loss and enteral feeding, and demographic and clinical factors (age, gender, nutritional status, total dose of radiotherapy, concurrent chemotherapy, disease stage, prior surgery, hyper-fractionation and performance status) were assessed.

RESULTS: The prevalence of weight loss ≥5% was 31% (median weight loss 8%, range 5-19%). The prevalence of commencement of enteral nutrition was 12%. Patients receiving concurrent chemotherapy were more likely to have ≥5% weight loss (40 versus 0%, phi = 0.35, p < 0.001). The odds of a patient with late stage disease having ≥5% weight loss were 15 times greater than for a patient with earlier disease stage (95% CI 1.97, 122.8, p = 0.009). Only Patient Generated Subjective Global Assessment score was associated with starting enteral nutrition (r = 0.27, p = 0.03).

CONCLUSION: Clinically significant weight loss is prevalent in lung cancer patients receiving radiotherapy and is associated with concurrent chemotherapy and late stage disease. Identification of factors associated with weight loss assists with early identification and intervention in patients at high nutritional risk.

Original languageEnglish
Pages (from-to)1074-80
Number of pages7
JournalClinical Nutrition
Volume33
Issue number6
DOIs
Publication statusPublished - Dec 2014
Externally publishedYes

Fingerprint

Weight Loss
Lung Neoplasms
Radiotherapy
Enteral Nutrition
Therapeutics
Drug Therapy
Nutritional Status
Non-Small Cell Lung Carcinoma
Thorax
Retrospective Studies
Demography

Cite this

@article{c220b27b9d664fb1862569eb5e7f5ae9,
title = "The prevalence of weight loss during (chemo)radiotherapy treatment for lung cancer and associated patient- and treatment-related factors",
abstract = "BACKGROUND & AIMS: Thoracic radiotherapy is associated with toxicities that can adversely impact nutritional intake. This study aimed to investigate the prevalence and predictors of ≥5{\%} weight loss and commencement of enteral nutrition in lung cancer patients receiving radiotherapy.METHODS: A retrospective study of 96 patients treated with high dose palliative or radical radiotherapy for a primary diagnosis of small cell or non-small cell lung cancer. Weight loss was calculated between the start and up to 90 days from radiotherapy commencement. Associations between ≥5{\%} weight loss and enteral feeding, and demographic and clinical factors (age, gender, nutritional status, total dose of radiotherapy, concurrent chemotherapy, disease stage, prior surgery, hyper-fractionation and performance status) were assessed.RESULTS: The prevalence of weight loss ≥5{\%} was 31{\%} (median weight loss 8{\%}, range 5-19{\%}). The prevalence of commencement of enteral nutrition was 12{\%}. Patients receiving concurrent chemotherapy were more likely to have ≥5{\%} weight loss (40 versus 0{\%}, phi = 0.35, p < 0.001). The odds of a patient with late stage disease having ≥5{\%} weight loss were 15 times greater than for a patient with earlier disease stage (95{\%} CI 1.97, 122.8, p = 0.009). Only Patient Generated Subjective Global Assessment score was associated with starting enteral nutrition (r = 0.27, p = 0.03).CONCLUSION: Clinically significant weight loss is prevalent in lung cancer patients receiving radiotherapy and is associated with concurrent chemotherapy and late stage disease. Identification of factors associated with weight loss assists with early identification and intervention in patients at high nutritional risk.",
author = "Nicole Kiss and Elisabeth Isenring and Karla Gough and Meinir Krishnasamy",
note = "Copyright {\circledC} 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.",
year = "2014",
month = "12",
doi = "10.1016/j.clnu.2013.11.013",
language = "English",
volume = "33",
pages = "1074--80",
journal = "Clinical Nutrition",
issn = "0261-5614",
publisher = "Churchill Livingstone",
number = "6",

}

The prevalence of weight loss during (chemo)radiotherapy treatment for lung cancer and associated patient- and treatment-related factors. / Kiss, Nicole; Isenring, Elisabeth; Gough, Karla; Krishnasamy, Meinir.

In: Clinical Nutrition, Vol. 33, No. 6, 12.2014, p. 1074-80.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The prevalence of weight loss during (chemo)radiotherapy treatment for lung cancer and associated patient- and treatment-related factors

AU - Kiss, Nicole

AU - Isenring, Elisabeth

AU - Gough, Karla

AU - Krishnasamy, Meinir

N1 - Copyright © 2013 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

PY - 2014/12

Y1 - 2014/12

N2 - BACKGROUND & AIMS: Thoracic radiotherapy is associated with toxicities that can adversely impact nutritional intake. This study aimed to investigate the prevalence and predictors of ≥5% weight loss and commencement of enteral nutrition in lung cancer patients receiving radiotherapy.METHODS: A retrospective study of 96 patients treated with high dose palliative or radical radiotherapy for a primary diagnosis of small cell or non-small cell lung cancer. Weight loss was calculated between the start and up to 90 days from radiotherapy commencement. Associations between ≥5% weight loss and enteral feeding, and demographic and clinical factors (age, gender, nutritional status, total dose of radiotherapy, concurrent chemotherapy, disease stage, prior surgery, hyper-fractionation and performance status) were assessed.RESULTS: The prevalence of weight loss ≥5% was 31% (median weight loss 8%, range 5-19%). The prevalence of commencement of enteral nutrition was 12%. Patients receiving concurrent chemotherapy were more likely to have ≥5% weight loss (40 versus 0%, phi = 0.35, p < 0.001). The odds of a patient with late stage disease having ≥5% weight loss were 15 times greater than for a patient with earlier disease stage (95% CI 1.97, 122.8, p = 0.009). Only Patient Generated Subjective Global Assessment score was associated with starting enteral nutrition (r = 0.27, p = 0.03).CONCLUSION: Clinically significant weight loss is prevalent in lung cancer patients receiving radiotherapy and is associated with concurrent chemotherapy and late stage disease. Identification of factors associated with weight loss assists with early identification and intervention in patients at high nutritional risk.

AB - BACKGROUND & AIMS: Thoracic radiotherapy is associated with toxicities that can adversely impact nutritional intake. This study aimed to investigate the prevalence and predictors of ≥5% weight loss and commencement of enteral nutrition in lung cancer patients receiving radiotherapy.METHODS: A retrospective study of 96 patients treated with high dose palliative or radical radiotherapy for a primary diagnosis of small cell or non-small cell lung cancer. Weight loss was calculated between the start and up to 90 days from radiotherapy commencement. Associations between ≥5% weight loss and enteral feeding, and demographic and clinical factors (age, gender, nutritional status, total dose of radiotherapy, concurrent chemotherapy, disease stage, prior surgery, hyper-fractionation and performance status) were assessed.RESULTS: The prevalence of weight loss ≥5% was 31% (median weight loss 8%, range 5-19%). The prevalence of commencement of enteral nutrition was 12%. Patients receiving concurrent chemotherapy were more likely to have ≥5% weight loss (40 versus 0%, phi = 0.35, p < 0.001). The odds of a patient with late stage disease having ≥5% weight loss were 15 times greater than for a patient with earlier disease stage (95% CI 1.97, 122.8, p = 0.009). Only Patient Generated Subjective Global Assessment score was associated with starting enteral nutrition (r = 0.27, p = 0.03).CONCLUSION: Clinically significant weight loss is prevalent in lung cancer patients receiving radiotherapy and is associated with concurrent chemotherapy and late stage disease. Identification of factors associated with weight loss assists with early identification and intervention in patients at high nutritional risk.

U2 - 10.1016/j.clnu.2013.11.013

DO - 10.1016/j.clnu.2013.11.013

M3 - Article

VL - 33

SP - 1074

EP - 1080

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 6

ER -